Clinical data | |
---|---|
Trade names | Benicar |
Other names | Olmesartan medoxomil |
AHFS/Drugs.com | Monograph |
MedlinePlus | a603006 |
License data |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 26% |
Metabolism | Liver (cannot be removed by hemodialysis) |
Elimination half-life | 13 hours |
Excretion | Kidney 40%, bile duct 60% |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.174.243 |
Chemical and physical data | |
Formula | C29H30N6O6 |
Molar mass | 558.595 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Olmesartan, sold under the brand name Benicar among others, is a medication used to treat high blood pressure (hypertension).[1][2] It is taken orally (swallowed by mouth).[2] Versions are available as the combination olmesartan/hydrochlorothiazide and olmesartan/amlodipine.[2] It is available as a prodrug, olmesartan medoxomil.
Common side effects include dizziness, headaches, diarrhea, and back pain.[2] Serious side effects may include kidney problems, low blood pressure, and angioedema.[2] Use in pregnancy may harm the fetus and use when breastfeeding is not recommended.[3] It is an angiotensin II receptor antagonist and works by blocking the effects of angiotensin II.[2]
It was patented in 1991 and came into medical use in 2002.[4] It is available as a generic medication.[5] In 2022, it was the 97th most commonly prescribed medication in the United States, with more than 6 million prescriptions.[6][7]